AI and automation integration halves the time and cost of new drug development [Korean]
In a groundbreaking development, Insilico Medicine’s CEO Alex Zhavoronkov highlights the integration of AI and automation in drug discovery, significantly reducing time and costs. Their innovative platform, Pharma.AI, has led to the successful identification of promising drug candidates, showcasing the transformative potential of AI in the pharmaceutical industry.